Accueil › Cancer colorectal › Michigan › Detroit
Essais cliniques pour Cancer colorectal à Detroit, MI
26 études pour Cancer colorectal recherchent des participants dans et autour de Detroit (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
The Vanguard Study: Testing a New Way to Screen for Cancer
Recrutement en coursVolontaires sains bienvenus
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
Recrutement en cours
- Henry Ford, Detroit
Family Communications After Genetic Testing
Recrutement en coursVolontaires sains bienvenus
- Henry Ford Health Saint John Hospital, Detroit
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Recrutement en coursPhase 2
- Henry Ford Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Recrutement en coursPhase 1
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Recrutement en coursPhase 3
- Henry Ford Hospital, Detroit
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Recrutement en coursPhase 3
- Henry Ford Hospital, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Recrutement en coursPhase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Recrutement en coursPhase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Recrutement en coursPhase 1/2
- GSK Investigational Site, Detroit
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Recrutement en coursPhase 3
- Henry Ford Hospital, Detroit
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Recrutement en coursPhase 3
- Clinical Study Site, Detroit
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Recrutement en coursPhase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1/2
- Karmanos Cancer Institute, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Recrutement en coursPhase 1
- Investigative Site #120, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1
- Henry Ford Health System, Detroit
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Recrutement en coursPhase 2
- Karmanos Cancer Center, Detroit
Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors
Recrutement en cours
- Karmanos Cancer Institute, Detroit
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Recrutement en coursPhase 1
- Karmanos Cancer Institute, Detroit
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Recrutement en coursPhase 1
- Henry Ford Health System, Detroit
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Recrutement en coursPhase 3Volontaires sains bienvenus
- Henry Ford Health Saint John Hospital, Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Recrutement en coursPhase 1/2
- Karmanos Cancer Institute, Detroit
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Recrutement en coursPhase 1
- Henry Ford Cancer-Detroit, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Recrutement en coursPhase 1
- Henry Ford Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Recrutement en coursPhase 1/2
- Karmanos Cancer Institute, Detroit
Essais pour Cancer colorectal dans d'autres villes
- Houston, TX102 études
- New York City, NY78 études
- Nashville, TN69 études
- Boston, MA63 études
- Los Angeles, CA59 études
- Arlington, VA52 études
- St. Louis, MO50 études
- San Antonio, TX46 études
- Philadelphia, PA44 études
- Grand Rapids, MI40 études
- Baldwin Park, CA37 études
- Chicago, IL34 études
Autres études à Detroit
- Cancer du poumon non à petites cellules44 études
- Cancer du sein33 études
- Cancer (tous types)29 études
- Cancer de l'ovaire26 études
- Cancer métastatique24 études
- Cancer de la prostate22 études
- Cancer de l'endomètre21 études
- Cancer du poumon20 études
- Myélome multiple19 études
- Cancer de l'estomac16 études
- Carcinome épidermoïde de la tête et du cou15 études
- Leucémie aiguë myéloïde14 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.